-
Sector Analysis
South America Fiber Cement Siding Market Summary, Competitive Analysis and Forecast to 2028
Fiber Cement Siding in South America industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2019-23, and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Key Highlights - Fiber cement siding is an exterior covering material for homes and commercial buildings. It is composed of Portland cement, cellulose fibers, and silica, and is available in the form of...
-
Product Insights
NewEbolavirus Infections (Ebola Hemorrhagic Fever) – Drugs In Development, 2024
Empower your strategies with our Ebolavirus Infections (Ebola Hemorrhagic Fever) – Drugs In Development, 2024 report and make more profitable business decisions. Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain, and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids, and pain relievers. The Ebolavirus Infections (Ebola Hemorrhagic Fever) drugs in development market...
-
Product Insights
NewInfluenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2024
Empower your strategies with our Influenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2024 report and make more profitable business decisions. H1N1 infection, also known as swine flu, is a new kind of flu in humans caused by a contagious influenza virus strain. H1N1 flu infects the nose, throat, and lungs. It is spread by droplets distributed by coughing or sneezing. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache, and fatigue. Treatment...
-
Product Insights
NewSeasonal Influenza – Drugs In Development, 2024
Empower your strategies with our Seasonal Influenza – Drugs In Development, 2024 report and make more profitable business decisions. Seasonal influenza, commonly referred to as "the flu", is a contagious respiratory illness caused by influenza viruses. It typically occurs in outbreaks during the fall and winter months, peaking between December and February in the Northern Hemisphere. The flu can cause mild to severe illness and, in some cases, can lead to hospitalization or even death, especially among vulnerable populations. Symptoms of...
-
Product Insights
NewPlague – Drugs In Development, 2024
Empower your strategies with our Plague – Drugs In Development, 2024 report and make more profitable business decisions. Plague is an infection caused by the bacterium Yersinia pestis. The organism is transmitted to humans who are bitten by fleas that have fed on infected rodents, or when human handle infected animals. Symptoms include headache, fatigue or malaise, muscle aches, fever and chills, abdominal pain, diarrhea and vomiting, shock, and bleeding from the mouth, nose, ectum, or under the skin. Treatment includes...
-
Product Insights
NewAplastic Anemia – Drugs In Development, 2024
Empower your strategies with our Aplastic Anemia – Drugs In Development, 2024 report and make more profitable business decisions. Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness, and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases,...
-
Product Insights
NewClostridioides difficile Infections (Clostridium difficile Associated Disease) – Drugs In Development, 2024
Empower your strategies with our Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or "C. diff", a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection include watery diarrhea with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool, and weight loss. Risk...
-
Product Insights
NewInfluenzavirus B Infections – Drugs In Development, 2024
Empower your strategies with our Influenzavirus B Infections – Drugs In Development, 2024 report and make more profitable business decisions. Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite, and weakness. Treatment includes antivirals, analgesics, and antipyretics medications. The Influenzavirus B Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Influenzavirus B...
-
Product Insights
NewInfluenzavirus A Infections – Drugs In Development, 2024
Empower your strategies with our Influenzavirus A Infections – Drugs In Development, 2024 report and make more profitable business decisions. Influenza A virus infections are caused by a type of influenza virus with a high capacity for genetic variation. It is more serious than the common cold and can cause major outbreaks and severe disease. It spreads through droplets from the nose or throat of an infected person, usually through coughing and sneezing. The proteins on the surface of the influenza...
-
Product Insights
NewNet Present Value Model: SAB Biotherapeutics Inc’s SAB-176
Empower your strategies with our Net Present Value Model: SAB Biotherapeutics Inc's SAB-176 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.